Yes, Value-based Contracting Does Have a Heartbeat
A few weeks ago, we sent a Report asking whether value-based (VB) contracting had a heartbeat. Today we have evidence that a meaningful heartbeat has been
June 7, 2023
A few weeks ago, we sent a Report asking whether value-based (VB) contracting had a heartbeat. Today we have evidence that a meaningful heartbeat has been
From time to time we run across an article that offers more than just recent industry news. Today we stumbled across an article that we suggest
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
The FDA recently approved a new subcutaneous therapy, Epkinly (epcoritamab-bysp) from Genmab, for the treatment of adult patients with relapsed or refractory (R/R) diffuse large
The FDA just approved a new rare, GENE therapy, Vyjuvek (beremagene geperpavec-svdt) from Krystal Biotech, indicated for the treatment of patients six months of age
A survey just released by the Pharmaceutical Strategies Group confirmed what we already know….. that the COST of specialty medications is the tipppty toppest key concern of
The hottest topic in the media these days is Artificial Intelligence (AI). It seems like everyone is talking about it. But that may be short sighted if
The FDA recently approved a new subcutaneous specialty therapy, Uzedy (risperidone) from TEVA and MedinCell, an atypical antipsychotic indicated for the treatment of schizophrenia in
We’ve reported several times on the disparity of specialty drug pricing based on where the drugs are administered. None of our readers would be surprised that
The FDA recently approved a new gene therapy, Omisirge (omidubicel-onlv) from Gamida Cell Ltd., for use in adult and pediatric patients (12 years and older)
